Product Description: Price

Isocitrate dehydrogenase (IDH) is an essential enzyme of the Krebs cycle (TCA Cycle). There are three isoforms: IDH1 (peroxisomes and cytosol NADP dependent), IDH2 (mitochondria NADP dependent), and IDH3 (mitochondria NAD dependent). The enzymes catalyze oxidative decarboxylation of isocitrate to α-ketoglutarate (α-KG) with generation of carbon dioxide and NADH or NADPH. IDH catalyzes one of the irreversible reactions in the cycle and therefore must be regulated to avoid unnecessary depletion of isocitrate, i.e., the enzyme is allosterically activated by ADP and inhibited by ATP or NADH/NADPH. Mutations in IDH1 and IDH2 genes are prevalent in myeloid malignancies and certain solid tumors, and these mutations are considered gain-of-function, leading to increased conversion of α-KG to 2-hydroxyglutarate, which can affect DNA methylation, histone methylation, receptor signaling, and cell growth. Enasidenib and ivosidenib, oral inhibitors of mutated IDH2 and IDH1, respectively, have been approved for use in relapsed or refractory acute myeloid leukemia. The IDH enzyme activity assay is based on the reduction of INT in a NAD+- or NADP+-coupled reaction to formazan, which exhibits an absorption maximum at 492 nm (Molar extinction coefficient=18 mM-1cm-1) and allows for sensitive measurement of IDH activity. Reagents are stable for several years if stored and handled properly.

​#IsocitrateDehydrogenase #IDH #KrebsCycle #TCACycle

Kit Components:

IDH3 Assay Solution: 5 ml, store at -80°C (for 100 wells)

10x IDH Substrate: 0.5 ml, store at -80ºC

10x Cell Lysis Solution: 25 ml, store at 4ºC

SDS:

TX-100, DMSO, INT, Tris

Related Kits:

MDH Assay, alpha-Ketoglutarate Dehydrogenase Assay